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Abstract In vivo, hormone-sensitive lipase (HSL) is known to be phosphorylated on two sites termed the regulatory and basal sites. However, the 
intracellular role of the basal site or the identity of the protein kinase phosphorylating this site has not been established. We show that 5-amino4 
imidazolecarboxamide r bonucleoside (AICAR) markedly activates cellular AMP-activated protein kinase (AMPK) in a time- and dose-dependent 
manner. As expected for an agent hat activates AMPK intracellularly, AICAR had no effect on the basal activity of HSL. However, preincubation 
of aclipocytes with AICAR led to a reduced response of these cells to the lipolytic agent isoprenaline. AICAR was also shown to profoundly inhibit 
lipogenesis through increased phosphorylation f acetyl-CoA carboxylase (ACC). Thus it appears that in addition to regulating lipogenesis, AMPK 
also plays an important antilipolytic role by regulating HSL in rat adipocytes. 
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1. Introduction 
Hormone-sensitive lipase (HSL) is the rate-limiting enzyme 
for the mobilisation of free fatty acids from adipose tissue and 
acetyl CoA carboxylase (ACC) is the key enzyme involved in 
the de nova biosynthesis of long-chain fatty acids. Both en- 
zymes are regulated by acute and long term mechanisms, with 
the latter involving changes in gene expression [l-3]. 
Short-term regulation of the activity of ACC involves com- 
plex allosteric modulation and reversible protein phosphoryla- 
tion [4]. Experimental data from several studies with intact cells 
and in vivo have shown that the increased phosphorylation and 
concomitant inactivation of ACC in response to both 
hormones and dietary manipulations is regulated by AMPK 
[5,6]. Furthermore, in rat hepatocytes and Fao hepatoma cells, 
it has been demonstrated that conditions which raise intracellu- 
lar 5’-AMP levels, e.g. treatment with ATP depletors [7’J, fruc- 
tose [8], heat shock or arsenite [9], cause a transient but marked 
activation of AMPK leading to concomitant inhibition of ACC 
and consequently fatty acid biosynthesis [7-g]. 
The hydrolysis of triacylglycerol by HSL is tightly controlled 
by a variety of hormonal and neural signals. Lipolytic agents 
such as adrenaline and isoprenaline acutely regulate HSL by 
raising CAMP levels to cause activation of CAMP-dependent 
protein kinase (PKA) which in turn phosphorylates and acti- 
vates HSL leading to the stimulation of lipolysis [lo,1 11. PK.4 
has been shown to phosphorylate a single site on HSL in vitro 
[ 12,131 and additional studies have shown that this site, termed 
the regulatory site, is also phosphorylated in primary rat adi- 
pocytes in response to lipolytic agents [12]. A second site, 
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termed the basal site, has also been shown to be partially 
phosphorylated in purified preparations of the enzyme suggest- 
ing that this may also occur in vivo [12]. Although a number 
of protein kinases phosphorylate the basal site in vitro, they 
have no direct effect on the activity of HSL. However, recent 
work has shown that in vitro phosphorylation of the basal site 
by AMPK, Ca2+/cahnodulin-dependent protein kinase or gly- 
cogen synthase kinase 4 prevents phosphorylation and subse- 
quent activation of HSL by PKA [14]. On the basis of these in 
vitro data, it has been suggested that phosphorylation of the 
basal site plays a physiological role in the regulation of lipolysis 
[14]. However, to date, there has been no progress to determine 
whether this mechanism operates in vivo and if so, which pro- 
tein kinase(s) is involved. 
Clearly, one approach to determine which protein kinase(s) 
is important in the phosphorylation of the basal site within HSL 
in vivo is to identify agents that activate these kinases in pri- 
mary adipocytes and examine their effects on lipolysis. Re- 
cently, we identified a number of 5’-AMP analogues that acti- 
vate rat and human liver AMPKs in vitro [ 151. In this study we 
show that 5-amino-4-imidazolecarboxamide ribonucleoside 
(AICAR), the cell-permeable precursor of 5-amino-4-imidazol- 
ecarboxamide ribotide (ZMP) [16], activates AMPK in primary 
adipocytes resulting in the inhibition of lipolysis and lipogene- 
sis. 
2. Materials and methods 
Collagenase was purchased from Worthington Biochemical Corpo- 
ration (UK). [T-~~P]ATP, [“Clbicarbonate and [3-3H&lucose were pur- 
chased from Amersham International. Optiscint Hisafe was purchased 
from Wallac (Milton Keynes, UK). All other reagents were purchased 
from Sigma Chemical Co (UK) unless otherwise indicated. 
2.1. Isolation of primary rat adipocytes 
Isolated adipocytes were obtained from the epiclidymal fat pads of 
fed rats (Alderley Park, 156200 g) by collagenase digestion [17]. Aliq- 
uots of fat cells (1 x 106 cells/ml) were incubated in polyethylene tubes 
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in Krebs-Ringer-HEPES buffer @H 7.4) supplemented with 1% (w/v) 
BSA at 37°C and agitated at 65 rpm for 1 h prior to use. 
2.2. AMPK and ACC assays 
Triplicate aliquots of adipocytes were incubated for 1 h (37”C, 65 
rpm) in polyethylene tubes in Krebs-Ringer-HEPES buffer @H 7.4) 
supplemented with 1% (w/v) BSA with or without AICAR (as indicated 
in the figure legends). The cells were separated from the media by 
flotation, resuspended in Buffer A (PH 7.2 at 4°C 100 mM Tris-HCl, 
250 mM Mannitol, 1 mM EDTA, 50 mM NaF, 5 mM sodium pyro- 
phosphate, 1 mM DTT, 1 mM benzamidine, 5pg/ml trypsin inhibitor) 
and immediately frozen in liquid nitrogen. Upon defrosting, the cellular 
debris was pelleted by centrifuging at 13,000 r.p.m for 3 min and the 
resulting supematant removed and adjusted to 6% with polyethylene 
glycol (PEG). Following further centrifugation for 5 min (13,000 rpm), 
the pellet was resuspended in Buffer A. Aliquots were used to assay the 
AMPK activity by the SAMS peptide phosphorylation assay in the 
presence of saturating (200 PM) concentrations of 5’-AMP as previ- 
ously described [15]. The initial activity of ACC was assayed by meas- 
uring the incorporation of [‘4C]bicarbonate into malonyl-CoA [18]. 
Each reaction mixture contained 100 mM Tris-HCl pH 7.4, 0.3 mM 
acetyl-CoA, 4 mM ATP, 2 mM MgCl, 10 mglml bovine serum albumin, 
15 mM Na[L4CJHC0, (2 Ciimol) and an aliquot of the resuspended 
PEG pellet fraction containing ACC. 
Trisodium citrate and equimolar MgClz were at 10 mM. Assays were 
terminated after 5 min at 37°C using 5 M HCl. Tubes were centrifuged 
at 13,000 r.p.m. for 2 min and an aliquot of the supematant was 
evaporated to dryness. Residues were dissolved in Hz0 and assayed for 
radioactivity in PCS scintillation fluid. For total activity measurements, 
ACC was prepared in Buffer A lacking NaF and sodium pyro- 
phosphate and incubated for 30 min at 37’C prior to assay. 
2.3. Measurement of lipolysis 
Triplicate aliquots of adipocytes were incubated with AICAR for 
1 h (37”C, 65 rpm) as in section 2.2. Following incubation, the cells were 
then challenged with isoprenaline (lo+’ to 10e5M) in 0.3 mM ascorbate 
for 30 min (37”C, 65 rpm). An aliquot of medium was removed and 
assayed for glycerol using Triglyceride Reagent A. Concentrations of 
glycerol were determined spectrophotometrically at a wavelength of 
590 nm with reference to a standard calibration curve over the range 
1-125 mg/dl. 
2.4. Measurement of lipogenesir 
Lipogenesis was measured according to the method of Moody et al. 
[19]. Triplicate aliquots of adipocytes were preincubated for 30 min 
(conditions described in section 2.1) in the presence of 1 nM insulin and 
then for a further 60 min in the absence or presence of AICAR and 
radiolabelled glucose (0.5 mM, 0.6 Cilmol). Reactions were terminated 
by addition of Optiscint fluid, mixed thoroughly and left to settle for 
60 min. An aliquot of the top phase was removed and counted for 
incorporation of tritiated glucose into total lipid. 
2.5. Other methods and analysis 
The SAMS peptide was synthesised as described previously [15]. 
Kinetic parameters were analysed by non-linear regression using 
Graph-Fit software. 
3.Results 
3.1. Activation of adipocyte AMP kinase 
We have recently shown that ZMP can mimic S-AMP by 
allosterically activating both rat and human liver AMPK in 
vitro [15]. The results presented here show that rat adipocyte 
AMPK is also activated by both S-AMP and ZMP. With 
5’-AMP, the V,, was 76 + 5 pmol/min/ lo6 cells with a X, for 
the peptide of 35,uM. With ZMP, the V_ was 55 + 3 pmoll 
min/106 cells with a iQ, of 103 PM. The kinetic constants show 
that ZMP is a weaker activator of adipocyte AMPK compared 
to 5’-AMP (V-/K,,, - 4-fold lower). 
To determine the intracellular effects of ZMP on AMPK 
activity, we used the cell permeable nucleoside precursor of 
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Fig. 1. Effects of a dose response to AICAR in primary adipocytes. (Panel A) Activation of PEG-purilied AMPK by AICAR expressed as pmol 
“P incorporated into the SAMS peptide/min/million cells. Samples were assayed in the presence of saturating concentrations of 5’-AMP (200 PM). 
(Panel B) Inhibition of lipolysis by AICAR expressed as nmol glycerol released/min/million cells. (Panel C) Inhibition of lipogenesis by AICAR 
expressed as nmol glucose incorporated into total lipid/min/million cells. (Panel D) Inhibition of ACC activity by AICAR expressed as nmol 
[“‘Clbicarbonate incorporated into malonyl CoA/min/million cells. In all experiments the data points represent he mean of three separate cell 
incubations. The standard deviations from the mean are indicated by the vertical bars. The statistical significance of differences, as determined by 
a two-tailed t-test, is indicated (***P c 0.001, **P < 0.002). 
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Fig. 2. Effect of AICAR on lipolysis stimulated by isoprenaline in 
primary adipocytes. Adipocytes were incubated for 60 min in control 
experiments (*) or with 500 ,uM AICAR (0) prior to a challenge with 
isoprenaline. The data points represent he mean of three separate cell 
incubations. The standard deviations from the mean are indicated by 
the vertical bars. The statistical significance of differences, as deter- 
mined by a two-tailed t-test, is indicated (***P < 0.001, *P < 0.01). 
ZMP, i.e. AICAR [16]. Preliminary experiments revealed that 
incubation of adipocytes with 500 PM AICAR increased the 
activity of partially purified AMPK in a time-dependent man- 
ner, AMPK activity following AICAR treatment reached a 
maximum by 30-60 min and remained elevated for approxi- 
mately 120 min before returning to control levels (data not 
shown). Fig. 1A shows that AICAR activates cellular AMPK 
in a dose-dependent manner with the maximum stimulation 
(-3-fold measured in the presence of a saturating concen- 
tration of 5’-AMP) being achieved at a concentration of ap- 
proximately 500pM. 
3.2. Effects of AICAR on lipolysis 
Preliminary experiments howed that neither basal or isopre- 
naline stimulated lipolysis could be inhibited when subse- 
quently challenged with 500 PM AICAR for 1 h (data not 
shown). However, as shown in Fig. 2, preincubation of adi- 
pocytes with 500 ,uM AICAR followed by incubation with lo-’ 
to lo-’ M isoprenaline produced a shift to the right in the 
dose-response curve, with AICAR increasing the EC,, of iso- 
prenaline from 5 f 1 nM to 20 f 9 nM. In addition, preincuba- 
tion of adipocytes with O-500 ,uM AICAR for 60 min followed 
by incubation with 10 nM isoprenaline produced a dose-de- 
pendent inhibition of isoprenaline-stimulated lipolysis 
(Fig. 1B). 
3.3. Effects of AICAR on lipogenesis and acetyl-coA 
carboxylase activity 
Incubation of rat adipocytes with AICAR led to a profound 
inhibition of lipogenesis in a dose-dependent manner (Fig. 1C). 
We also obtained a similar dose-dependent inhibition of 
[3H]glucose incorporation into fatty acids when total lipids were 
saponified and the extracted fatty acids counted (data not 
shown). Based on our earlier observation of a dose-dependent 
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activation of cellular AMPK by AICAR, we investigated 
whether the inhibitory effects of AICAR on lipogenesis were 
mediated through inhibition of ACC. Polyethylene glycol pre- 
cipitates from AICAR-treated adipocytes were assayed for 
ACC activity in the presence of 10 mM citrate. As shown in Fig. 
lD, AICAR caused a marked decrease in the V_ of ACC 
resulting in a 40% inhibition of activity with 500 ,uM AICAR. 
To further investigate the mechanisms by which AICAR 
inhibits ACC activity, the ACC in PEG pellets from control and 
AICAR treated adipocytes was prepared and resuspended in 
buffer with or without the phosphatase inhibitors NaF and 
sodium pyrophosphate. The results in Fig. 3 show that the 
inhibitory effects of AICAR on ACC activity can be reversed 
in vitro if the enzyme is prepared and assayed under conditions 
where endogenous protein phosphatases are likely to be active 
[20,21]. In addition, the reactivation of ACC by endogenous 
phosphatases can be blocked by the phosphatase inhibitor oka- 
daic acid (Fig. 3). Taken together, these results suggest hat the 
inhibitory action of AICAR on ACC is most likely due to 
increased phosphorylation of the enzyme by AMPK. 
4. Discussion 
Phosphorylation of HSL in intact rat adipocytes occurs on 
two distinct sites termed the basal and regulatory sites although 
the physiological role of the basal site is not clear. Nevertheless, 
it has been proposed that by phosphorylating the basal site, 
AMPK plays an antilipolytic role in vivo [14]. Recently, we 
have identified several analogues of 5’-AMP that activate rat 
and human AMPKs in vitro [15]. Clearly, agents that can acti- 
vate AMPK in isolated cells would be useful in determining the 
role of this protein kinase in lipolysis. 
Our results show that AICAR markedly activates AMPK in 
adipocytes in a time and dose-dependent manner. Although we 
have not measured ZMP levels in cellular extracts, it is likely 
that the effect of AICAR on AMPK activity is mediated by a 
rise in the intracellular concentration of ZMP, since AICAR 
CONTROL AICAR 
Fig. 3. Effect of AICAR on the phosphorylation state of ACC. Adi- 
uocvtes were incubated with or without 5OOuM AICAR for 60 min and 
ACk isolated and assayed in buffer con&ining 50 mM NaF/S mM 
sodium pyrophosphate or 500 nM okadaic acid or buffer without phos- 
phatase inhibitors. 100% activity is defined as the activity of ACC 
isolated from adipocytes in the absence of phosphatase inhibitors. The 
data points represent the mean of five separate xperiments (except for 
okadaic acid where 2 experiments were performed), with the standard 
deviations from the mean indicated by the vertical bars. 
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also increases ZMP in other cell types [16,22]. The fact that the 
increased activity of AMPK survives partial purification sug- 
gests that the stimulation of AMPK by AICAR involves cova- 
lent modification of the kinase. This is supported by the obser- 
vation that the increased activity of AMPK is detectable when 
the allosteric site is saturated (Fig. IA) The most likely mecha- 
nism for the observed effects is an increased phosphorylation 
of AMPK, catalysed by the AMP-activated protein kinase ki- 
nase (AMPKK) in response to raised intracellular levels of the 
5’-AMP analogue, ZMI? Recent work has shown that the phos- 
phorylation and activation of AMPK by AMPKK is markedly 
stimulated by AMP. This effect appears to be mediated by the 
binding of S-AMP to AMPK [9] and so it is likely that ZMP 
can mimic this effect. 
As anticipated, incubation of adipocytes with AICAR had 
no effect on the basal activity of HSL. However, the response 
of adipocytes to isoprenaline was markedly reduced if these 
cells were first preincubated with AICAR. The need for a pre- 
incubation step with AICAR is consistent with earlier in vitro 
data which shows that phosphorylation of HSL by AMPK 
prevents its subsequent activation [ 141. 
AICAR also profoundly inhibits lipogenesis by increasing 
the phosphorylation of ACC, an enzyme known to be regulated 
by AMPK in cells and in vivo [8,23]. Evidence from other 
studies also shows that activation of AMPK leads to a recipro- 
cal inactivation of its cellular targets, i.e. ACC and HMG-CoA 
reductase [7,9,24]. Additionally, a previous report has shown 
that AICAR profoundly inhibits both ACC and HMG-CoA 
reductase activities in primary rat hepatocytes, presumably by 
activating cellular AMPK [25]. 
We believe that our results provide the first cellular evidence 
to support the concept that AMPK plays a role in the physio- 
logical regulation of HSL. Further studies with AICAR and 
other cell-permeable activators of AMPK will investigate the 
mechanism(s) by which AMPK prevents activation of HSL. 
AMPK activators should also prove useful for studying the role 
of this kinase in the regulation of other cellular processes. 
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